Table 1.
ECRSwNP | NECRSwNP | |
n (%) | 27 (45%) | 33 (55%) |
Age (yr), mean ± SD | 46.93 ± 12.35 | 40.27 ± 13.47 |
M/F | 20/7 | 24/9 |
With AR (%) | 74.10% | 48.5% |
With asthma (%) | 18.50% | 12.1% |
Duration of symptom (yr) | 5.50 ± 3.92 | 8.55 ± 6.93 |
VAS | 4.04 ± 1.01 | 3.99 ± 1.09 |
Score of olfactory dysfunction | 5.59 ± 2.54 | 5.21 ± 2.66 |
Score of polyps | 3.59 ± 1.11b | 2.06 ± 0.82 |
Incidence of bilateral polyps | 92.6%b | 39.9% |
Score of disease on CT | 14.42 ± 3.84b | 9.64 ± 3.37 |
Serum IgE (kU/L) | 236.72 ± 157.77 | 167.97 ± 176.77 |
Blood eosinophil count (× 109/L) | 0.44 ± 0.24b | 0.21 ± 0.11 |
Blood eosinophil percentage (%) | 6.49 ± 3.27b | 3.42 ± 1.87 |
Tissue eosinophil count/HPF | 31.56 ± 21.37b | 0.91 ± 0.80 |
P < 0.01 vs NECRSwNP. ECRSwNP: Eosinophilic chronic rhinosinusitis with nasal polyps; NECRSwNP: Non-eosinophilic chronic rhinosinusitis with nasal polyps; M/F: Male/female; AR: Allergic rhinitis; VAS: Visual analogue scale; HPF: High power field; CT: Computed tomography.